Andreas Halvorsen: portfolio of Viking Global Investors
Andreas Halvorsen leads Viking Global Investors, a hedge fund that analyzes stocks worldwide and combines long and short positions.
Source: 13F filing with the US Securities and Exchange Commission dated Aug 14, 2023. It shows positions at quarter end and is filed up to 45 days later – today the positions may be several months old. It covers only securities traded on US exchanges, without short positions; securities traded only abroad and cash are not included. Form 13F filingInvestment managers with discretion over at least 100 million USD in reportable US securities (mainly stocks and ETFs, plus options and convertible bonds) report their holdings to the SEC within 45 days after each quarter. Short positions, securities traded only abroad and cash are not included.Example: Positions as of 30 Sep, filed on 14 Nov → they are already six weeks old when published.More in the Academy: Glossary
You are looking at Q2 2023. Go to the latest filing (Q3 2026)
- Total value of stock positions
- 24.3B USD
- Positions
- 85
- Share of the ten largest
- 37.4%
The ten largest positions Q2 2023
- Visa Inc. 7.0%▲ +8.8%
- Danaher Corporation 4.2%new
- Api Group Corp 3.8%▲ +0.3%
- Philip Morris International 3.6%new
- UnitedHealth Group 3.5%▼ −14.6%
- GE Aerospace 3.2%▼ −17.1%
- Roivant Sciences Ltd 3.1%▼ −14.7%
- Meta Platforms 3.1%▼ −19.7%
- Fortive 3.0%▲ +54.4%
- Workday, Inc. 2.8%▲ +373.0%
Show all positions of this quarter
Choose a quarter (54 filings)
- Q3 2026
- Q2 2026
- Q1 2026
- Q4 2025
- Q3 2025
- Q2 2025
- Q1 2025
- Q4 2024
- Q3 2024
- Q2 2024
- Q1 2024
- Q4 2023
- Q3 2023
- Q2 2023
- Q1 2023
- Q4 2022
- Q3 2022
- Q2 2022
- Q1 2022
- Q4 2021
- Q3 2021
- Q2 2021
- Q1 2021
- Q4 2020
- Q3 2020
- Q2 2020
- Q1 2020
- Q4 2019
- Q3 2019
- Q2 2019
- Q1 2019
- Q4 2018
- Q3 2018
- Q2 2018
- Q1 2018
- Q4 2017
- Q3 2017
- Q2 2017
- Q1 2017
- Q4 2016
- Q3 2016
- Q2 2016
- Q1 2016
- Q4 2015
- Q3 2015
- Q2 2015
- Q1 2015
- Q4 2014
- Q3 2014
- Q2 2014
- Q1 2014
- Q4 2013
- Q3 2013
- Q2 2013
All positions Q2 2023
| Symbol | Weight | Shares | Reported value | Change | Held since |
|---|---|---|---|---|---|
| AMZN Amazon | 2.4% | 4,401,313 | 573.8M USD | −42.3% reduced | Q2 2015 33 quarters |
| MSFT Microsoft | 1.7% | 1,202,051 | 409.3M USD | +14.8% increased | Q2 2016 29 quarters |
| V Visa Inc. | 7.0% | 7,140,286 | 1.7B USD | +8.8% increased | Q3 2016 28 quarters |
| Bridgebio Pharma Inc | 1.9% | 26,620,991 | 457.9M USD | unchanged | Q2 2019 17 quarters |
| Adaptive Biotechnologies Cor | 0.8% | 29,993,708 | 201.3M USD | unchanged | Q2 2019 17 quarters |
| FTV Fortive | 3.0% | 9,798,229 | 732.6M USD | +54.4% increased | Q3 2019 16 quarters |
| Guardant Health Inc | 0.2% | 1,594,326 | 57.1M USD | −37.2% reduced | Q3 2019 16 quarters |
| CB Chubb Limited | 0.8% | 970,942 | 187.0M USD | −72.0% reduced | Q1 2020 14 quarters |
| Api Group Corp | 3.8% | 34,199,532 | 932.3M USD | +0.3% increased | Q2 2020 13 quarters |
| TMO Thermo Fisher Scientific | 1.8% | 833,233 | 434.7M USD | −2.8% reduced | Q2 2020 13 quarters |
| Royalty Pharma PLC | 1.2% | 9,850,932 | 302.8M USD | −12.1% reduced | Q2 2020 13 quarters |
| Karuna Therapeutics Inc | 0.8% | 947,955 | 205.6M USD | −36.8% reduced | Q3 2020 12 quarters |
| Inhibrx Inc | 0.7% | 6,639,199 | 172.4M USD | unchanged | Q3 2020 12 quarters |
| GE GE Aerospace | 3.2% | 7,138,176 | 784.1M USD | −17.1% reduced | Q4 2020 11 quarters |
| META Meta Platforms | 3.1% | 2,594,548 | 744.6M USD | −19.7% reduced | Q4 2020 11 quarters |
| Acadia Healthcare Company In | 1.1% | 3,240,894 | 258.1M USD | −3.4% reduced | Q4 2020 11 quarters |
| 4D Molecular Therapeutics In | 0.4% | 4,787,914 | 86.5M USD | +21.6% increased | Q4 2020 11 quarters |
| Kinnate Biopharma Inc | < 0.1% | 1,820,462 | 5.5M USD | unchanged | Q4 2020 11 quarters |
| AMP Ameriprise Financial | 1.5% | 1,124,103 | 373.4M USD | +19.5% increased | Q1 2021 10 quarters |
| Zai Lab Ltd | 0.3% | 2,629,445 | 72.9M USD | +12.8% increased | Q1 2021 10 quarters |
| Pharvaris N V | 0.2% | 3,231,923 | 50.8M USD | unchanged | Q1 2021 10 quarters |
| Edgewise Therapeutics Inc | 0.2% | 5,943,261 | 46.1M USD | +21.1% increased | Q1 2021 10 quarters |
| Day One Biopharmaceuticals I | 0.1% | 2,558,563 | 30.5M USD | +64.2% increased | Q2 2021 9 quarters |
| Hdfc Bank Ltd | 2.7% | 9,312,208 | 649.1M USD | +12.4% increased | Q3 2021 8 quarters |
| Ginkgo Bioworks Holdings Inc | 1.1% | 143,085,126 | 266.1M USD | unchanged | Q3 2021 8 quarters |
| Rallybio Corp | < 0.1% | 4,194,777 | 23.7M USD | unchanged | Q3 2021 8 quarters |
| Roivant Sciences Ltd | 3.1% | 75,238,700 | 758.4M USD | −14.7% reduced | Q4 2021 7 quarters |
| Biomarin Pharmaceutical Inc | 1.5% | 4,156,785 | 360.3M USD | +91.7% increased | Q4 2021 7 quarters |
| IFF International Flavors & Fragrances | 1.2% | 3,569,966 | 284.1M USD | +339.3% increased | Q4 2021 7 quarters |
| Lianbio | < 0.1% | 3,564,173 | 8.1M USD | unchanged | Q4 2021 7 quarters |
| ELV Elevance Health | 2.6% | 1,412,701 | 627.6M USD | −34.4% reduced | Q1 2022 6 quarters |
| MA Mastercard | 1.6% | 1,012,725 | 398.3M USD | +27.1% increased | Q1 2022 6 quarters |
| Unum Group | 1.0% | 5,271,387 | 251.4M USD | +23.9% increased | Q1 2022 6 quarters |
| Amylyx Pharmaceuticals Inc | 0.3% | 2,962,555 | 63.9M USD | unchanged | Q1 2022 6 quarters |
| PGR Progressive Corporation | 0.2% | 396,437 | 52.5M USD | −60.5% reduced | Q1 2022 6 quarters |
| INTU Intuit | 2.0% | 1,053,352 | 482.6M USD | −13.7% reduced | Q2 2022 5 quarters |
| MU Micron Technology | 1.1% | 4,424,339 | 279.2M USD | +54.9% increased | Q2 2022 5 quarters |
| MCK McKesson Corporation | 0.9% | 524,143 | 224.0M USD | −83.7% reduced | Q2 2022 5 quarters |
| Pepgen Inc | < 0.1% | 1,482,434 | 13.3M USD | −4.0% reduced | Q2 2022 5 quarters |
| UNH UnitedHealth Group | 3.5% | 1,794,275 | 862.4M USD | −14.6% reduced | Q3 2022 4 quarters |
| CDNS Cadence Design Systems | 1.7% | 1,750,247 | 410.5M USD | +42.8% increased | Q3 2022 4 quarters |
| Valvoline Inc | 1.2% | 7,682,814 | 288.2M USD | +3.8% increased | Q3 2022 4 quarters |
| Rogers Comms B | 0.3% | 1,764,200 | 80.5M USD | −68.2% reduced | Q3 2022 4 quarters |
| Trevi Therapeutics Inc | < 0.1% | 4,400,000 | 10.5M USD | unchanged | Q3 2022 4 quarters |
| FTNT Fortinet | 2.4% | 7,689,287 | 581.2M USD | −35.3% reduced | Q4 2022 3 quarters |
| CSX CSX Corporation | 1.8% | 12,806,951 | 436.7M USD | −41.9% reduced | Q4 2022 3 quarters |
| Seagate Technology Hldngs Pl | 0.8% | 3,186,400 | 197.1M USD | −42.2% reduced | Q4 2022 3 quarters |
| Kbr Inc | 0.3% | 1,203,207 | 78.3M USD | −28.4% reduced | Q4 2022 3 quarters |
| Newamsterdam Pharma Company | 0.3% | 6,524,565 | 77.6M USD | +66.6% increased | Q4 2022 3 quarters |
| Farfetch Ltd | 0.1% | 4,769,602 | 28.8M USD | −32.9% reduced | Q4 2022 3 quarters |
“Held since”: the first quarter from which the position appears in the 13F filing at every quarter end. It first appears at the end of that quarter – the filing gives neither date nor price, and trading between two quarter ends is not visible. “Or earlier”: the position was already in the first available filing (or the first one after a gap in filings). After a change of the security identifier (e.g. a renaming) the start may appear later.
Show more (up to 500) Shown: the 50 longest-held of 85 positions.
Plus 1 position in convertible bonds and bonds worth 86.4M USD as reported – not included in the weights.
Convertible bonds and bonds, principal amount as reported. They are not stock positions and therefore do not count towards the weights.
- Guardant Health Inc principal 120.0M USD 86.4M USD
Breakdown by sector
- Technology 14.8%
- Health Care 13.0%
- Financials 12.6%
- Industrials 9.4%
- Consumer Discretionary 5.4%
- Consumer Staples 4.4%
- Communication Services 4.2%
- Materials 4.2%
- Real Estate 1.5%
- Utilities 0.4%
- not in our coverage 30.1%
Sectors only for stocks we cover; the rest is grouped under “not in our coverage”.
How to read this page
- Weight: a position’s share of the total value of all reported stock positions in this quarter – options and bonds are not counted.
- Change: number of shares compared with the previous quarter. After a stock split we convert the previous quarter’s share count so that a split does not look like an increase; if a possible split cannot be confirmed, “–” is shown.
- Reported value: value of the position at quarter end as reported by the investor. The portfolio may have changed since then.
All superinvestor portfolios Screener: stocks held by superinvestors